CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
ItalianoCILLONI, Daniela
Dettaglio
CILLONI, Daniela
SCIENZE CLINICHE E BIOLOGICHE
Pubblicazioni
Risultati 1 - 20 di 226 (tempo di esecuzione: 0.001 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | A very sensitive and rapid method for BCR-ABL T315Imutation detection by peptide nucleic acid directed PCR clamping | 2009 | E. Bracco; M. Spagna; R. Pedrola; V. Rosso; F. Arruga; M. Lo Iacono; S. Carturan; F. Messa; C. Panuzzo; P. Nicoli; E. Messa; A. Rotolo; A. Morotti; S. Mussino; A. Balbo; D. Cilloni; S.G. Saglio |
| 2 | A young man with persistent eosinophilia | 2007 | MESSA E; CILLONI D; SAGLIO G |
| 3 | A. HHV8-positive, HIV-negative multicentric Castleman's disease:early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma | 2009 | Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A. |
| 4 | Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. | 2013 | Cilloni D; Carturan S; Bracco E; Campia V; Rosso V; Torti D; Calabrese C; Gaidano V; Niparuck P; Favole A; Signorino E; Iacobucci I; Morano A; De Luca L; Musto P; Frassoni F; Saglio G. |
| 5 | ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia | 2005 | SOVERINI S; MARTINELLI G; ROSTI G; BASSI S; AMABILE M; POERIO A; GIANNINI B; TRABACCHI E; CASTAGNETTI F; TESTONI N; LUATTI S; DE VIVO A; CILLONI D; IZZO B; FAVA M; ABRUZZESE E; ALBERTI D; PANE F; SAGLIO G; BACCARANI M. |
| 6 | Abl: the prototype of oncogenic fusion proteins | 2004 | G. SAGLIO; D. CILLONI |
| 7 | Absence of Spred, a Negative Regulator of Tyrosine Kinase Activity, in Acute Myeloid Leukemia Patients | 2012 | Rosso V; Panuzzo C; Bracco E; Carturan S; Campia V; Favole A; Signorino E; Niparuk P; Calabrese C; De Luca L; Caivano A; Morano A; Frassoni F; Saglio G; Cilloni D |
| 8 | Absence of Spred1, a negative regulator of Ras/MAPK pathway, as a mechanism responsible for the constitutive activation of RTK mediated signalling in acute leukemias | 2005 | Cilloni D; Bracco E; Defilippi I; Messa F; Carturan S; Di Giovanni D; Arruga F; Rosso V; Catalano R; Messa E; Morotti A; Serra A; Saglio G |
| 9 | Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients | 2006 | IACOBUCCI I; SAGLIO G; ROSTI G; TESTONI N; PANE F; AMABILE M; POERIO A; SOVERINI S; BASSI S; CILLONI D; BASSAN R; BRECCIA M; LAURIA F; IZZO B; MERANTE S; FRASSONI F; PAOLINI S; MONTEFUSCO E; BACCARANI M; MARTINELLI G; GIMEMA WORKING; PARTY ON CHRONIC MYELOID LEUKEMIA |
| 10 | Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. | 2012 | S. Galimberti;F. Guerrini;F. Salvi;I. Petrini;D. Gioia;E. Messa;G. A. Palumbo;D. Cilloni;M. Petrini;A. Levis |
| 11 | Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. | 2002 | GUERRASIO A; PILATRINO C; DE MICHELI D; D. CILLONI; SERRA A; GOTTARDI E; PARZIALE A; MARMONT F; DIVERIO D; DIVONA M; LO COCO F; SAGLIO G. |
| 12 | Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. | 2013 | Angelini S; Soverini S; Ravegnini G; Barnett M; Turrini E; Thornquist M; Pane F; Hughes TP; White DL; Radich J; Kim DW; Saglio G; Cilloni D; Iacobucci I; Perini G; Woodman R; Cantelli-Forti G; Baccarani M; Hrelia P; Martinelli G. |
| 13 | Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients | 2020 | Bertolotto A.; Martire S.; Mirabile L.; Capobianco M.; De Gobbi M.; Cilloni D. |
| 14 | Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms | 2020 | Petiti J.; Lo Iacono M.; Rosso V.; Andreani G.; Jovanovski A.; Podesta M.; Lame D.; Gobbi M.D.; Fava C.; Saglio G.; Frassoni F.; Cilloni D. |
| 15 | The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias | 2016 | Carrà, Giovanna; Torti, Davide; Crivellaro, Sabrina; Panuzzo, Cristina; Taulli, Riccardo; Cilloni, Daniela; Guerrasio, Angelo; Saglio, Giuseppe; Morotti, Alessandro |
| 16 | Cardiovascular events and intensity of treatment in polycythemia vera | 2013 | Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T; CYTO-PV Collaborative Group |
| 17 | CD7/CD56-positive acute myeloid leukemias are characterized by constitutive phosphorylation of the NF-kB subunit p65 at Ser536 | 2007 | Morotti A; Parvis G; Cilloni D; Familiari U; Pautasso M; Bosa M; Messa F; Arruga F; Defilippi I; Catalano R; Rosso V; Carturan S; Bracco E; Guerrasio A; Saglio G. |
| 18 | CD7/CD56-positive acute myeloid leukemias are characterized by constitutive phosphorylation of the NF-kB subunit p65 at Ser536. | 2007 | Morotti A;Parvis G;Cilloni D;Familiari U;Pautasso M;Bosa M;Messa F;Arruga F;Defilippi I;Catalano R;Rosso V;Carturan S;Bracco E;Guerrasio A;Saglio G |
| 19 | Characterization and monitoring by droplet digital PCR of a novel BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia | 2020 | Petiti J, Dragani M, Castelli A, Lo Iacono M, Fantino C, Badino C, Serra A, Giugliano E, Andreani G, Rosso V, Gottardi E, Rege-Cambrin G, Saglio G, Cilloni D, Fava C. |
| 20 | Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib | 2012 | White DL; Radich J; Soverini S; Saunders VA; Frede AK; Dang P; Cilloni D; Lin P; Mongay L; Woodman R; Manley P; Slader C; Kim DW; Pane F; Martinelli G; Saglio G; Hughes TP. |
Copyright © 2022